EC backs nanotechnology with 1 billion euro
The European Commission (EC) has made 1 billion euro available for new projects involving micro and nanotechnology.
The European Commission (EC) has made 1 billion euro available for new projects involving micro and nanotechnology. The amount will come from the EC's Information Communications Technology and Nanoscience, Nanotechnology, Materials and New Production Processes (NMP) funds as part of the Framework Programme 7 (FP7).
"European FP7 enables organizations, through collaborative R&D, to access new partners, skills and knowledge in the development of their future products and services," Alastair McGibbon, the UK FP7 national contact point for NMP, said in a statement.
The UK's Nanotechnology Knowledge Transfer Network (NanoKTN) is very supportive of the funds, which could provide a boost for pharma. "Nanotechnology is being increasingly used by the pharmaceutical industry in two areas: drug discovery, where smaller assay volumes are used and greater information is obtained; and formulation, where nanocarriers improve bioavailability and efficacy," Mike Fisher, BioNano Theme Manager at NanoKTN, explained to Pharmaceutical Technology Europe. "Adoption has been relatively slow, but this is because companies need to see a clear path to market."
Several calls for funding have now been scheduled during the next 9 months. The first deadline is 8 December 2009. According to NanoKTN, the UK, as well as the rest of Europe, could stand to benefit from this funding. "Nanotechnologies and microtechnologies are being recognized as important means of wealth and job creation for the UK and Europe, and successful development and uptake of new technology is central to the UK's wealth creation in the next 20 years," Alec Reader, Director of NanoKTN, said in the press statement.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
